Skip to main content
. 2022 Mar 25;12:5164. doi: 10.1038/s41598-022-09048-5

Figure 4.

Figure 4

Calculated frequencies of the mutations when half of the population of cancer stem cells is no longer wild-type. Calculations were performed for cells treated with imatinib, ponatinib, or a rotation of the drugs.